Toyocamycin (Standard)
DL-Aspartic acid (Standard) is the analytical standard of DL-Aspartic acid. This product is intended for research and analytical applications. DL-Aspartic acid (DL-Asp-OH) is a kind of biological materials or organic compounds that are widely used in life science research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 606-58-6
- Formel: C12H13N5O4
- Molecular Weight:291.26
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Alle Antibiotic Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
IC50: 80 nM (XBP1 activation)[1]; 79 nM (CDK9); 2.8 μM (CDK7); 0.67 μM (CDK2), 15 μM (CDK4), >10 μM (CDK6)[2]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-431 | IC50 |
3.3 μg/mL
Compound: toyocamycin
|
Inhibition of phosphatidylinositol 4-kinase in human A431 cell membrane by liquid scintillation counting
Inhibition of phosphatidylinositol 4-kinase in human A431 cell membrane by liquid scintillation counting
|
[PMID: 1666120] |
| B16 | EC50 |
0.005 μM
Compound: toyocamycin
|
Cytotoxicity that caused a 50% reduction in absorbance at 490 nm in B16 mouse melanoma cells using MTS assay.
Cytotoxicity that caused a 50% reduction in absorbance at 490 nm in B16 mouse melanoma cells using MTS assay.
|
[PMID: 11020285] |
| BSC-1 | IC50 |
46 μM
Compound: a
|
Tested in vitro for cytotoxicity against the monkey kidney cells (BSC-1 cells).
Tested in vitro for cytotoxicity against the monkey kidney cells (BSC-1 cells).
|
[PMID: 2175356] |
| HFF | IC50 |
8 μM
Compound: a
|
Tested in vitro for cytotoxicity against the normal human diploid cells (HFF cells).
Tested in vitro for cytotoxicity against the normal human diploid cells (HFF cells).
|
[PMID: 2175356] |
| HFF | IC50 |
0.03 μM
Compound: 8b
|
Cytotoxicity was evaluated against the Human diploid cells (HFF)
Cytotoxicity was evaluated against the Human diploid cells (HFF)
|
[PMID: 2913300] |
| HFF | IC50 |
<0.01 μM
Compound: I
|
Cytotoxicity against HFF cells, estimated by visual scoring of cells not affected by virus infection in the plaque reduction assay
Cytotoxicity against HFF cells, estimated by visual scoring of cells not affected by virus infection in the plaque reduction assay
|
[PMID: 8632411] |
| KB | IC50 |
17 μM
Compound: a
|
Tested in vitro for cytotoxicity against the human neoplastic cell line (KB cells).
Tested in vitro for cytotoxicity against the human neoplastic cell line (KB cells).
|
[PMID: 2175356] |
| KB | IC50 |
0.04 μM
Compound: 8b
|
Cytotoxicity was evaluated in Human neoplastic cell line (KB)
Cytotoxicity was evaluated in Human neoplastic cell line (KB)
|
[PMID: 2913300] |
| KB | IC50 |
0.03 μM
Compound: I
|
Cytotoxic activity tested against exponentially growing KB cells, determined by staining method
Cytotoxic activity tested against exponentially growing KB cells, determined by staining method
|
[PMID: 8632411] |
| L1210 | IC50 |
0.0026 μg/mL
Compound: 2
|
Cytotoxicity against mouse L1210 cells
Cytotoxicity against mouse L1210 cells
|
[PMID: 2693614] |
| Vero C1008 | EC50 |
0.59 μM
Compound: Toyocamycin
|
Antiviral activity against SARS-CoV-2 infected in African green monkey Vero E6 cells assessed as reduction in infection measured after 24 hrs by Plaque assay
Antiviral activity against SARS-CoV-2 infected in African green monkey Vero E6 cells assessed as reduction in infection measured after 24 hrs by Plaque assay
|
[PMID: 37229831] |
Chemical Information
-
CAS. Nr. 606-58-6
-
Molecular Weight 291.26
-
Formel C12H13N5O4
-
SMILES
O[C@H]1[C@@H](O[C@H](CO)[C@H]1O)N2C3=C(C(N)=NC=N3)C(C#N)=C2
-
Synonyms
Vengicide (Standard)
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
[1]. Toyocamycin, et al. Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing. Blood Cancer J. 2012 Jul;2(7):e79. [Content Brief]
[2]. Pandey S, et al. Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells. Cancers (Basel). 2022 Jul 8;14(14):3340. [Content Brief]
[3]. Park SG, et al. Toyocamycin induces apoptosis via the crosstalk between reactive oxygen species and p38/ERK MAPKs signaling pathway in human prostate cancer PC-3 cells. Pharmacol Rep. 2017 Feb;69(1):90-96. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Toyocamycin (Standard) Related Classifications
HY-103248R Related Classifications
Powered by Bioz
- Toyocamycin (Standard)
- 606-58-6
- Vengicide (Standard)
- Reference Standards
- IRE1
- Fungal
- Antibiotic
- Apoptosis
- CDK
- adenosine analog
- RNA synthesis
- ribosome function
- mRNA cleavage
- CDKs
- CDK9 inhibitor
- toyocamycin
- drug screening
- epigenetics
- cancer
- RNA Pol II phosphorylation
- molecular docking
- extracellular signal-regulated kinases
- reactive oxygen species
- Inhibitor
- inhibitor
- inhibit